{"page":{"totalFilteredElements":330},"studies":[{"active":true,"description":"

Reduktion postoperativer Hernien nach Laparotomien durch small stitch Bauchdeckenverschluss ohne vs. mit prophylaktischer Netzimplantation

DRKS00017517

","eudractNumber":null,"id":6661,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_10","name":"Phase IIIB"},"recruitmentStart":"2020-01-14T10:21:02+01:00","shortTitle":"HULC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label

DRKS00033264
","eudractNumber":null,"id":10626,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-01T14:53:16+01:00","shortTitle":"Harbour","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Stereotactic body\nradiotherapy (SBRT) for primary liver tumors (HepReg) - an International Multicentre Registry Collecting Data on Patients treated with SBRT for HCC","eudractNumber":null,"id":10200,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2026-03-02T13:32:31+01:00","shortTitle":"HepReg","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Establishment of a national registry for the Evaluation and improvement of Risk-adjusted prevention for hereditary breast and ovarian cancer","eudractNumber":null,"id":6724,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2021-01-01T13:47:32+01:00","shortTitle":"HerediCaRe","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":12056,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-03-30T08:24:39+02:00","shortTitle":"Hi WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom
Evaluation der Wirksamkeit, Sicherheit und Lebensqualität der Behandlung mit Ivosidenib
","eudractNumber":null,"id":11564,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-10-06T09:14:01+02:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Neuer zielgerichteter Therapieansatz beim IDH1 R132- mutierten Cholangiokarzinom
Evaluation der Wirksamkeit, Sicherheit und Lebensqualität der Behandlung mit Ivosidenib
","eudractNumber":null,"id":10706,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-11-11T15:59:15+01:00","shortTitle":"IDHIRA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
Phase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)

Target: PRAME
","eudractNumber":"2019-002370-31","id":5992,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PRAME (Nuclear Receptor Transcriptional Regulator)","id":"mt_171"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT03686124","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2020-08-13T12:47:21+02:00","shortTitle":"IMA203-101 (Immatics-PRAME)","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, \nTolerability and Anti-Tumor Activity of IMA402, a Bispecific T \nCell-Engaging Receptor Molecule (TCER®) targeting PRAME, in \nPatients with Recurrent and/or Refractory Solid Tumors","eudractNumber":"2022-503133-54","id":8735,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"sar","name":"Sarkome"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PRAME (Nuclear Receptor Transcriptional Regulator)","id":"mt_171"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT05958121","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2023-09-15T11:57:08+02:00","shortTitle":"IMA402-101","therapeutical":true,"therapyLines":[{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)","eudractNumber":"2023-510292-65-00","id":11651,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06585774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T12:53:35+01:00","shortTitle":"INCA034176-357","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}